140PD: LUX-Lung 7: A Phase IIb, global, randomised, open-label trial of afatinib vs gefitinib as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations.
JOURNAL OF THORACIC ONCOLOGY（2016）
关键词
egfr mutations,lux-lung cancer,gefitinib,afatinib,open-label,first-line,non-small
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要